SynthesisBMC pulmonary medicine2025
Efficacy and safety of anlotinib combined with immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer: a meta-analysis based on real-world data.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis research intended to ascertain the clinical efficacy and safety of anlotinib plus immune checkpoint inhibitors (ICIs) in patients suffering from extensive-stage small cell lung cancer (ES-SCLC).
methodsAcademic databases, encompassing PubMed, Embase, and the Cochrane Library, were retrieved to aggregate pertinent research, published up to March 5, 2025. The primary outcome measures covered progression-free survival (PFS), median PFS (mPFS), overall survival (OS), disease control rate (DCR), and objective response rate (ORR). Additionally, secondary outcome measures comprised partial response (PR), complete response (CR), stable disease (SD), and progressive disease (PD).
resultsData pooled from 18 distinct studies, including 1,698 individuals, were synthesized and analyzed. The results revealed a statistically meaningful increase in PFS and OS for patients who received anlotinib combined with ICIs, as opposed to those receiving chemotherapy alone. Furthermore, with regard to improving ORR and DCR, anlotinib plus ICIs was significantly more efficacious than anlotinib monotherapy and chemotherapy monotherapy (P < 0.05). In comparison to chemotherapy monotherapy, anlotinib plus ICIs exhibited a notably elevated risk of thrombocytopenia (OR: 1.7, 95% CI: 1.19–2.43, P = 0.0034). However, when compared with anlotinib monotherapy, anlotinib plus ICIs did not elevate the incidence of severe adverse events (≥ grade 3). Subgroup analysis results indicated that the Eastern Cooperative Oncology Group (ECOG) performance status (PS) served as an independent predictor influencing both PFS and OS outcomes in individuals with SCLC. In contrast, neither brain metastases nor liver metastases emerged as independent prognostic factors influencing PFS and OS.
conclusionThis investigation indicates that anlotinib plus ICIs can extend PFS, elevate ORR and DCR, and prolong OS in individuals with SCLC. This meta-analysis offers new insights into the treatment paradigm for SCLC, indicating that anlotinib plus ICIs can substantially ameliorate clinical outcomes in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.